GLP-1 and type 2 diabetes: physiology and new clinical advances

被引：33

作者：

Combettes, Murielle M. J. ^{[1
]}

机构：

[1] Inst Rech Servier, SERVIER, Div Malad Metab, F-92150 Suresnes, France

来源：

CURRENT OPINION IN PHARMACOLOGY | 2006年 / 6卷 / 06期

关键词：

D O I：

10.1016/j.coph.2006.08.003

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The first antidiabetic treatment (exenatide; Byetta) based on the incretin hormone glucagon-like peptide-1 (GLP-1) was approved in 2005 as an adjunctive therapy in diabetic patients in whom sulfonylurea, metformin or both had failed. Many GLP-1 mimetics or dipeptidyl peptidase IV inhibitors are currently in clinical development for the treatment of type 2 diabetes and show promising results in the improvement of glucose homeostasis. Furthermore, the ability of GLP-1 to enhance pancreatic P-cell mass could delay progression of the disease. However, only several years of treatment in humans will confirm the long-term efficacy of GLP-1 mimetics and enhancers on glycemic control. To take advantage of the multifaceted actions of GLP-1, a better understanding of the physiological roles of GLP-1 is required.

引用

页码：598 / 605

页数：8

共 59 条

[1] Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice [J].

Ahrén, B .

AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2004, 286 (02) :R269-R272

[2]

AHREN B, 2006, CURR MOL MED, V13, P154, DOI DOI 10.1097/01.MED.0000216964.28881.BA

[3] Therapeutic approaches to preserve islet mass in type 2 diabetes [J].

Baggio, LL ;

Drucker, DJ .

ANNUAL REVIEW OF MEDICINE, 2006, 57 :265-281

[4] Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms [J].

Balkan, B ;

Li, X .

AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2000, 279 (04) :R1449-R1454

[5] Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes [J].

Blonde, L. ;

Klein, E. J. ;

Han, J. ;

Zhang, B. ;

Mac, S. M. ;

Poon, T. H. ;

Taylor, K. L. ;

Trautmann, M. E. ;

Kim, D. D. ;

Kendall, D. M. .

DIABETES OBESITY & METABOLISM, 2006, 8 (04) :436-447

[6]

Bojanowska E, 2005, MED SCI MONITOR, V11, pRA271

[7] Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury [J].

Bose, AK ;

Mocanu, MM ;

Carr, RD ;

Brand, CL ;

Yellon, DM .

DIABETES, 2005, 54 (01) :146-151

[8] Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system [J].

Brubaker, PL ;

Drucker, DJ .

ENDOCRINOLOGY, 2004, 145 (06) :2653-2659

[9] Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor [J].

Burcelin, R ;

Da Costa, A ;

Drucker, D ;

Thorens, B .

DIABETES, 2001, 50 (08) :1720-1728

[10] Transcription factor Fox01 mediates glucagon-like peptide-1 effects on pancreatic β-cell mass [J].

Buteau, J ;

Spatz, ML ;

Accill, D .

DIABETES, 2006, 55 (05) :1190-1196

← 1 2 3 4 5 6 →